Pharmacodynamic and Pharmacokinetic Dose Ranging Study of Tiotropium Bromide Administered Via Respimat Device in Patients With Chronic Obstructive Pulmonary Disease (COPD)

NCT02175342 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

202

Enrollment

INDUSTRY

Sponsor class

Conditions

Pulmonary Disease, Chronic Obstructive

Interventions

DRUG: Tiotropium 0.625 mcg/puff
DRUG: Tiotropium 1.25 mcg/puff
DRUG: Tiotropium 2.5 mcg/puff
DRUG: Tiotropium 5 mcg/puff
DRUG: Placebo solution
DRUG: Tiotropium-18 lactose powder
DRUG: Placebo lactose powder
DRUG: Tiotropium 10 mcg/puff
DEVICE: Respimat
DEVICE: Handihaler

Sponsor

Boehringer Ingelheim